Journal: mBio
Article Title: Evolutionary dynamics of heparan sulfate utilization by SARS-CoV-2
doi: 10.1128/mbio.01303-25
Figure Lengend Snippet: TMPRSS2 cleaves cell surface HS proteoglycans. ( A ) Binding of WT or BA.1 RBD-Fc, anti-syndecan-1 (SDC1) Ab, anti-glypican-4 (GPC4) Ab, anti-HS Ab, anti-ACE2 Ab, anti-HLA class I Ab, anti-integrin αV (CD51) Ab, anti-CD46 Ab, or anti-CD59 Ab to HEK293T cells pretreated with (red line) or without (black line) trypsin. ( B ) Representative gating strategy for TMPRSS2-negative (GFP neg , black), low-expressing (GFP low , blue), or high-expressing (GFP high , red) cells in TMPRSS2/GFP-Tf HEK293T cells. ( C ) Top: representative histograms showing the binding of WT or BA.1 RBD-Fc, anti-SDC1 Ab, anti-GPC4 Ab, anti-HS Ab, anti-ACE2 Ab, anti-HLA class I Ab, anti-CD51 Ab, anti-CD46 Ab, or anti-CD59 Ab to TMPRSS2-negative (black line, GFP neg ), low-expressing (blue line, GFP low ) or high-expressing (red line, GFP high ) cells. Bottom: quantification of binding is shown as GMFI. ( D ) Infection of D614G or BA.1 pseudovirus to mock or ACE2-Tf HEK293T cells with (+) or without (–) TMPRSS2 expression. ( E ) Infection of authentic SARS-CoV-2 WT or BA.1.18 variant to mock or ACE2-Tf HEK293T cells with (+) or without (–) TMPRSS2 expression. Viral RNA in cell lysates at 24 hours post-inoculation is shown. Lysate RNA was normalized to Actb . Data are mean ± SEM of three to four technical replicates. Statistical analysis was performed using two-way ANOVA with Sidak’s multiple comparison tests in panel D and unpaired two-tailed Welch’s t -tests between WT and BA.1.18 in panel E ; * P < 0.05, ** P < 0.01, and **** P < 0.0001; ns, not significant. Data are representative of two to three independent experiments.
Article Snippet: Mouse anti-human ACE2 monoclonal antibody (mAb) (AC384, Adipogen), mouse anti-HS mAb (F58-10E4, Amzbio), mouse anti-CS mAb (CS-56, Sigma-Aldrich), rat anti-Flag-tag mAb (L5, BioLegend), mouse anti-human CD138 (syndecan-1) mAb (MI15, BioLegend), mouse anti-human glypican-4 mAb (961609, R&D Systems), mouse anti-human CD46 mAb (J4.48, Beckman), mouse anti-human CD59 mAb (p282[H19], BioLegend), mouse anti-human HLA class I mAb (W6/32, Institute of Development, Aging and Cancer, University of Tohoku), mouse anti-human CD51 (integrin αV) mAb (L230, Enzo), Alexa Fluor 555 goat anti-mouse IgM (Heavy chain) Ab (Thermo Scientific), allophycocyanin (APC)-conjugated goat anti-human IgG, Fcγ fragment specific Ab, APC-conjugated goat anti-mouse IgG, Fcγ fragment specific Ab, APC-conjugated goat anti-mouse IgM, μ chain specific Ab, APC-conjugated donkey anti-rat IgG (H + L) Ab, and APC-conjugated streptavidin (Jackson) were used.
Techniques: Binding Assay, Expressing, Infection, Variant Assay, Comparison, Two Tailed Test